Be part of the knowledge.™

Pathology and Laboratory Medicine

84

LikeLikedUnlike

Episodes 16-30 of 46

Interprofessional Coordination of Adverse Event Management
MinuteCE®
Interprofessional Coordination of Adverse Event Management
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
MinuteCE®
Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
Maximizing Adherence and Persistence via Patient Engagement
MinuteCE®
Maximizing Adherence and Persistence via Patient Engagement
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence
MinuteCE®
Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
MinuteCE®
Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
MinuteCE®
High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
MinuteCE®
Precision Timing: Unveiling the Impact of CDK4/6 Inhibition in Early HR+/HER2- Breast Cancer
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 credits 10 episodes
Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC
MinuteCE®
Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
Treatment Intensification in HR+/HER2- EBC: Who and When?
MinuteCE®
Treatment Intensification in HR+/HER2- EBC: Who and When?
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
MinuteCE®
Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
- Hope S. Rugo, MD, FASCO
  Peer
- Nadia Harbeck, MD, PhD
  Peer
1.25 program credits
Identifying the Great Imitator – Demystifying the Systemic Features of IgG4-Related Disease
CME/CE Broadcast Replay
Identifying the Great Imitator – Demystifying the Systemic Features of IgG4-Related Disease
- John H. Stone, MD, MPH
  Peer
- Emanuel Della Torre, MD, PhD
  Peer
- Yoh Zen, MD, PhD, FRCPath
  Peer
1.00 credits
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
CME/CE
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
- Yasmin Genevieve Hernandez-Barco, MD
  Peer
- Avinash Kambadakone-Ramesh, MD, DNB, FRCR
  Peer
0.25 credits
IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis
CME/CE
IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis
- Emma Culver, BSc, MD, PhD, FRCP
  Peer
- Louisa Catherine Firmin, MBChB, MRCS, FRCR
  Peer
0.25 credits
IgG4-RD Case Conversations: The Peculiarities of Kidney Involvement
CME/CE
IgG4-RD Case Conversations: The Peculiarities of Kidney Involvement
- Giacomo Quattrocchio, MD
  Peer
- Lynn D. Cornell, MD
  Peer
0.50 credits
IgG4-RD Case Conversations: Systemic Disease Infiltrating the Skull Base
CME/CE
IgG4-RD Case Conversations: Systemic Disease Infiltrating the Skull Base
- John H. Stone, MD, MPH
  Peer
- Bart K. Chwalisz, MD
  Peer
- Marcela Marsiglia, MD, PhD
  Peer
0.50 credits

Program Chapters

Segment Chapters

Playlist:

Recommended